SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer
Ipilimumab-nivolumab shows activity in treatment-refractory granulosa cell tumors, with 25% (n = 2/8) of patients experiencing either CR or PR lasting more than 4 years.
Authors
- Emily M. Whitman-Purves
- John M. Schallenkamp (ORCID: https://orcid.org/0000-0003-1492-7168)
- Leonard J. Appleman (ORCID: https://orcid.org/0000-0003-4951-7388)
- Liam Il‐Young Chung (ORCID: https://orcid.org/0000-0001-6541-793X)
- Hye Sung Kim (ORCID: https://orcid.org/0000-0002-7256-7597)
- Elad Sharon (ORCID: https://orcid.org/0000-0002-0044-9719)
- Jayanthi Lea (ORCID: https://orcid.org/0000-0002-8657-4309)
- John Ellerton (ORCID: https://orcid.org/0009-0005-8205-2318)
- Megan Othus (ORCID: https://orcid.org/0000-0001-8176-6371)
- Charles D. Blanke
- Christopher W. Ryan (ORCID: https://orcid.org/0000-0002-4259-1123)
- Helen X. Chen (ORCID: https://orcid.org/0000-0001-9959-8417)
- Nabil Adra (ORCID: https://orcid.org/0000-0001-8905-8329)
- Razelle Kurzrock (ORCID: https://orcid.org/0000-0003-4110-1214)
- Jessica Thomes Pepin
- Sandip Pravin Patel (ORCID: https://orcid.org/0000-0002-8387-4840)
- Adam Walter (ORCID: https://orcid.org/0000-0001-5819-5160)
- William R. Robinson (ORCID: https://orcid.org/0009-0003-1429-4396)
- Andrew Poklepovic (ORCID: https://orcid.org/0000-0002-4015-5037)
- Young Kwang Chae (ORCID: https://orcid.org/0000-0003-1557-7235)
- G. López (ORCID: https://orcid.org/0009-0005-4174-9071)
- Christine M. McLeod
- Mitchell Alden
- HOWARD Z. STREICHER (ORCID: https://orcid.org/0000-0003-3683-9804)
- Murtuza Rampurwala (ORCID: https://orcid.org/0000-0002-2825-186X)
- Kelly J. Wilkinson
Institutions
- Northwestern University (US)
- Tulane University (US)
- Indiana University Health (US)
- Thomas Jefferson University (US)
- North Park University (US)
- University of San Diego (US)
- Oregon Health & Science University (US)
- University of Pittsburgh (US)
- Virginia Commonwealth University (US)
- Medical College of Wisconsin (US)
- Flower Hospital (US)
- University of Mississippi Medical Center (US)
- University of Mississippi (US)
- Southwestern Medical Center (US)
- Indiana Cancer Consortium (US)
- Temple University Hospital (US)
- Indiana University Bloomington (US)
- Metro-Minnesota Community Oncology Research Consortium (US)
- UPMC Hillman Cancer Center (US)
- Mark H. Zangmeister Cancer Center (US)
- National Cancer Institute (US)
- Doylestown Hospital (US)
- Metro Urology (US)
- Cancer Research Foundation (US)
- Data Management (Italy) (IT)
- SWOG Cancer Research Network (US)
- Indiana University – Purdue University Indianapolis (US)
- The University of Texas Southwestern Medical Center (US)
- Billings Clinic (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-0606
- Citations
- 11
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.91
Funders
- Bristol-Myers Squibb Foundation
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Northwestern University
- Regeneron Pharmaceuticals
- Novocure
- Lunit
- National Institutes of Health
- Genentech
- Foundation Medicine
- National Cancer Institute